NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
27/06/2023
Voltar para busca
Dado oficial do USPTO
KENOTA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Snapshot rápido
KENOTA
ST13
US500000088794131Classe
5, 9, 10, 42
Pedido
88794131
Registro
7089131
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
59
Atualização mais recente
27/06/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 9, 10, 42
Data de depósito
12/02/2020
Data de registro
27/06/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
27/06/2023
Última transação
27/06/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Foreign priority
Primeiro uso
05/01/2023
Primeiro uso no comércio
05/01/2023
Código do desenho
4
Tipo de titular
03
Localização do titular
Kitchener, Ontario, CA
Examinador
DUBOIS, SUSAN L
Unidade examinadora
M20
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Kenota Inc.
Representantes
Erika L. Jenkins, Esq. POMEROY LAW GROUP PLLC
Classificação técnica
Classes Nice
Classe 5Classe 9Classe 10Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Transdermal patches for use in medical diagnostics to treat allergiesinfectious diseasesneurological disorderscardiovascular diseasesskin disorderscancersendocrine disordersto monitor general health biomarkers for medical and veterinary purposes; transdermal patches for use in drug delivery and immunotherapy delivery applications to treat allergiesinfectious diseasesneurological disorderscardiovascular diseasesskin disorderscancersendocrine disordersto monitor general health biomarkers for medical and veterinary purposes; biochemical assays for testing body fluids for use in medical diagnostics and point-of-care diagnostics for medical and veterinary purposes
Classe 9
Computer hardware platform for use in medical diagnostics to treat allergiesinfectious diseasesneurological disorderscardiovascular diseasesskin disorderscancersendocrine disordersto monitor general health biomarkers for medical and veterinary purposes
Classe 10
Medical equipment in the nature of microfluidic testing systemsblood testing and analysis systemslateral flow assay testing systems for use in medical diagnostics to treat allergiesinfectious diseasesneurological disorderscardiovascular diseasesskin disorderscancersendocrine disordersto monitor general health biomarkers for medical and veterinary purposes; micro needles and finger-prick blood sample collection instruments for medical and veterinary purposes; medical deviceslancetssyringesblood collectorscartridgescartridge sleevesfor medical and veterinary purposes; medical devices for use in microfluidicspaper-based microfluidics and microfluidic chips for medical and veterinary purposes; finger prick needles for medical and veterinary purposes
Classe 42
Medical device research and development services for medical and veterinary purposes; research and development services in the area of in vitro diagnostics (IVD) for medical and veterinary purposes; point-of-care medical device research and development services for medical and veterinary purposes; research and development services in the area of allergy testing for medical and veterinary purposes; research and development services in the area of transdermal pharmaceutical drug delivery for medical and veterinary purposes; research and development services in the area of transdermal immunotherapy delivery for medical and veterinary purposes; all of the aforementioned services being performed for others
Publicações
Histórico de despachos e eventos da marca no USPTO.
59 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
27/06/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/04/2023
PUBO
PUBLISHED FOR OPPOSITION
11/04/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/03/2023
AAUA
NOTICE OF ACCEPTANCE OF AMENDMENT TO ALLEGE USE E-MAILED
07/03/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/03/2023
IUAA
USE AMENDMENT ACCEPTED
06/03/2023
AUPC
AMENDMENT TO USE PROCESSING COMPLETE
28/02/2023
IUAF
USE AMENDMENT FILED
28/02/2023
EAAU
TEAS AMENDMENT OF USE RECEIVED
27/02/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
23/02/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
23/02/2023
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
22/02/2023
DOCK
ASSIGNED TO EXAMINER
17/01/2023
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
28/11/2022
GNSL
LETTER OF SUSPENSION E-MAILED
28/11/2022
CNSL
SUSPENSION LETTER WRITTEN
28/11/2022
DOCK
ASSIGNED TO EXAMINER
26/10/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/10/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/10/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
25/10/2022
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
25/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/10/2022
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
16/08/2022
GNSI
INQUIRY TO SUSPENSION E-MAILED
16/08/2022
CNSI
SUSPENSION INQUIRY WRITTEN
16/08/2022
DOCK
ASSIGNED TO EXAMINER
12/08/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
29/06/2022
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
10/06/2022
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
15/11/2021
GNSL
LETTER OF SUSPENSION E-MAILED
15/11/2021
CNSL
SUSPENSION LETTER WRITTEN
15/11/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/09/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/09/2021
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
10/09/2021
ALIE
ASSIGNED TO LIE
10/09/2021
ERSI
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
02/09/2021
GNS2
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
16/08/2021
GNSI
INQUIRY TO SUSPENSION E-MAILED
16/08/2021
CNSI
SUSPENSION INQUIRY WRITTEN
16/08/2021
RCCK
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
04/08/2021
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/03/2021
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
04/03/2021
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
04/03/2021
GNS3
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
28/10/2020
GNSL
LETTER OF SUSPENSION E-MAILED
28/10/2020
CNSL
SUSPENSION LETTER WRITTEN
28/10/2020
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
08/10/2020
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/10/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/10/2020
GNRN
NOTIFICATION OF NON-FINAL ACTION E-MAILED
06/05/2020
GNRT
NON-FINAL ACTION E-MAILED
06/05/2020
CNRT
NON-FINAL ACTION WRITTEN
06/05/2020
DOCK
ASSIGNED TO EXAMINER
02/05/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
18/02/2020
NWAP
NEW APPLICATION ENTERED
15/02/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace KENOTA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.